blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

Italy joins the Federated Register

Click here for more information on the Federated Register.

2025-06-12

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register User Manual
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3102946

EP3102946 - DIAGNOSIS OF CANCER BY DETECTING AUTO-ANTIBODIES AGAINST VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  06.09.2019
Database last updated on 09.04.2026
FormerThe patent has been granted
Status updated on  28.09.2018
FormerGrant of patent is intended
Status updated on  21.09.2018
FormerExamination is in progress
Status updated on  17.08.2018
FormerGrant of patent is intended
Status updated on  26.03.2018
FormerExamination is in progress
Status updated on  11.08.2017
FormerRequest for examination was made
Status updated on  11.11.2016
Most recent event   Tooltip01.07.2022Lapse of the patent in a contracting state
New state(s): MK		published on 03.08.2022  [2022/31]
Applicant(s)For all designated states
CellTrend GmbH
Im Biotechnologiepark
14943 Luckenwalde / DE
[2016/50]
Inventor(s)01 / HEIDECKE, Harald
Im Gestell 5
14169 Berlin / DE
02 / SCHULZE-FORSTER, Kai
Goerzallee 21
12207 Berlin / DE
 [2018/42]
Former [2016/50]01 / HEIDECKE, Harald
Im Gestell 5
14169 Berlin / DE
02 / SCHULZE-FORSTER, Kai
Bertholdstr. 1a
14513 Teltow / DE
Representative(s)Vossius & Partner Patentanwälte Rechtsanwälte mbB
Siebertstrasse 3
81675 München / DE
[2016/50]
Application number, filing date15702482.903.02.2015
[2016/50]
WO2015EP52184
Priority number, dateEP2014015382304.02.2014         Original published format: EP 14153823
[2016/50]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2015117953
Date:13.08.2015
Language:EN
[2015/32]
Type: A1 Application with search report 
No.:EP3102946
Date:14.12.2016
Language:EN
The application published by WIPO in one of the EPO official languages on 13.08.2015 takes the place of the publication of the European patent application.
[2016/50]
Type: B1 Patent specification 
No.:EP3102946
Date:31.10.2018
Language:EN
[2018/44]
Search report(s)International search report - published on:EP13.08.2015
ClassificationIPC:A61P35/00, G01N33/564, G01N33/574
[2018/15]
CPC:
G01N33/57545 (EP,US); A61P35/00 (EP); C07K14/515 (US);
C07K16/2863 (US); C07K16/30 (US); C07K16/3069 (US);
G01N33/564 (EP,US); G01N33/74 (US); C07K2317/24 (US);
C07K2317/76 (US); G01N2333/475 (EP,US); G01N2800/52 (EP,US);
G01N2800/56 (EP,US); G16H10/40 (US); G16H50/20 (EP,US);
G16H50/30 (EP,US) (-)
Former IPC [2016/50]G01N33/564, G01N33/574, G01N33/74
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2016/50]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:DIAGNOSE VON KREBS DURCH DETEKTION VON AUTO-ANTIKÖRPERN GEGEN DEN VASKULÄREN ENDOTHELIALEN WACHSTUMSFAKTOR (VEGF)[2016/50]
English:DIAGNOSIS OF CANCER BY DETECTING AUTO-ANTIBODIES AGAINST VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF)[2016/50]
French:DIAGNOSTIC DE CANCER PAR LA DÉTECTION D'AUTO-ANTICORPS CONTRE LE FACTEUR DE CROISSANCE ENDOTHÉLIALE VASCULAIRE (VEGF)[2016/50]
Entry into regional phase05.09.2016National basic fee paid 
05.09.2016Designation fee(s) paid 
05.09.2016Examination fee paid 
Examination procedure15.08.2016Amendment by applicant (claims and/or description)
15.08.2016Date on which the examining division has become responsible
05.09.2016Examination requested  [2016/50]
09.08.2017Despatch of a communication from the examining division (Time limit: M04)
11.12.2017Reply to a communication from the examining division
27.03.2018Communication of intention to grant the patent
06.08.2018Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
06.08.2018Fee for grant paid
06.08.2018Fee for publishing/printing paid
20.09.2018Information about intention to grant a patent
20.09.2018Receipt of the translation of the claim(s)
Opposition(s)01.08.2019No opposition filed within time limit [2019/41]
Fees paidRenewal fee
27.02.2017Renewal fee patent year 03
23.02.2018Renewal fee patent year 04
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU03.02.2015
AL31.10.2018
AT31.10.2018
CY31.10.2018
CZ31.10.2018
DK31.10.2018
EE31.10.2018
ES31.10.2018
FI31.10.2018
HR31.10.2018
LT31.10.2018
LV31.10.2018
MC31.10.2018
MK31.10.2018
NL31.10.2018
PL31.10.2018
RO31.10.2018
RS31.10.2018
SE31.10.2018
SI31.10.2018
SK31.10.2018
SM31.10.2018
TR31.10.2018
BG31.01.2019
NO31.01.2019
GR01.02.2019
IE03.02.2019
LU03.02.2019
MT03.02.2019
BE28.02.2019
IS28.02.2019
PT01.03.2019
[2022/31]
Former [2021/32]HU03.02.2015
AL31.10.2018
AT31.10.2018
CY31.10.2018
CZ31.10.2018
DK31.10.2018
EE31.10.2018
ES31.10.2018
FI31.10.2018
HR31.10.2018
LT31.10.2018
LV31.10.2018
MC31.10.2018
NL31.10.2018
PL31.10.2018
RO31.10.2018
RS31.10.2018
SE31.10.2018
SI31.10.2018
SK31.10.2018
SM31.10.2018
TR31.10.2018
BG31.01.2019
NO31.01.2019
GR01.02.2019
IE03.02.2019
LU03.02.2019
MT03.02.2019
BE28.02.2019
IS28.02.2019
PT01.03.2019
Former [2021/26]AL31.10.2018
AT31.10.2018
CY31.10.2018
CZ31.10.2018
DK31.10.2018
EE31.10.2018
ES31.10.2018
FI31.10.2018
HR31.10.2018
LT31.10.2018
LV31.10.2018
MC31.10.2018
NL31.10.2018
PL31.10.2018
RO31.10.2018
RS31.10.2018
SE31.10.2018
SI31.10.2018
SK31.10.2018
SM31.10.2018
TR31.10.2018
BG31.01.2019
NO31.01.2019
GR01.02.2019
IE03.02.2019
LU03.02.2019
MT03.02.2019
BE28.02.2019
IS28.02.2019
PT01.03.2019
Former [2020/29]AL31.10.2018
AT31.10.2018
CZ31.10.2018
DK31.10.2018
EE31.10.2018
ES31.10.2018
FI31.10.2018
HR31.10.2018
LT31.10.2018
LV31.10.2018
MC31.10.2018
NL31.10.2018
PL31.10.2018
RO31.10.2018
RS31.10.2018
SE31.10.2018
SI31.10.2018
SK31.10.2018
SM31.10.2018
TR31.10.2018
BG31.01.2019
NO31.01.2019
GR01.02.2019
IE03.02.2019
LU03.02.2019
MT03.02.2019
BE28.02.2019
IS28.02.2019
PT01.03.2019
Former [2020/17]AL31.10.2018
AT31.10.2018
CZ31.10.2018
DK31.10.2018
EE31.10.2018
ES31.10.2018
FI31.10.2018
HR31.10.2018
LT31.10.2018
LV31.10.2018
MC31.10.2018
NL31.10.2018
PL31.10.2018
RO31.10.2018
RS31.10.2018
SE31.10.2018
SI31.10.2018
SK31.10.2018
SM31.10.2018
TR31.10.2018
BG31.01.2019
NO31.01.2019
GR01.02.2019
IE03.02.2019
LU03.02.2019
BE28.02.2019
IS28.02.2019
PT01.03.2019
Former [2020/12]AL31.10.2018
AT31.10.2018
CZ31.10.2018
DK31.10.2018
EE31.10.2018
ES31.10.2018
FI31.10.2018
HR31.10.2018
LT31.10.2018
LV31.10.2018
MC31.10.2018
NL31.10.2018
PL31.10.2018
RO31.10.2018
RS31.10.2018
SE31.10.2018
SI31.10.2018
SK31.10.2018
SM31.10.2018
BG31.01.2019
NO31.01.2019
GR01.02.2019
IE03.02.2019
LU03.02.2019
BE28.02.2019
IS28.02.2019
PT01.03.2019
Former [2020/09]AL31.10.2018
AT31.10.2018
CZ31.10.2018
DK31.10.2018
EE31.10.2018
ES31.10.2018
FI31.10.2018
HR31.10.2018
LT31.10.2018
LV31.10.2018
MC31.10.2018
NL31.10.2018
PL31.10.2018
RO31.10.2018
RS31.10.2018
SE31.10.2018
SI31.10.2018
SK31.10.2018
SM31.10.2018
BG31.01.2019
NO31.01.2019
GR01.02.2019
IE03.02.2019
LU03.02.2019
IS28.02.2019
PT01.03.2019
Former [2019/50]AL31.10.2018
AT31.10.2018
CZ31.10.2018
DK31.10.2018
EE31.10.2018
ES31.10.2018
FI31.10.2018
HR31.10.2018
LT31.10.2018
LV31.10.2018
MC31.10.2018
NL31.10.2018
PL31.10.2018
RO31.10.2018
RS31.10.2018
SE31.10.2018
SI31.10.2018
SK31.10.2018
SM31.10.2018
BG31.01.2019
NO31.01.2019
GR01.02.2019
LU03.02.2019
IS28.02.2019
PT01.03.2019
Former [2019/47]AL31.10.2018
AT31.10.2018
CZ31.10.2018
DK31.10.2018
EE31.10.2018
ES31.10.2018
FI31.10.2018
HR31.10.2018
LT31.10.2018
LV31.10.2018
MC31.10.2018
NL31.10.2018
PL31.10.2018
RO31.10.2018
RS31.10.2018
SE31.10.2018
SK31.10.2018
SM31.10.2018
BG31.01.2019
NO31.01.2019
GR01.02.2019
LU03.02.2019
IS28.02.2019
PT01.03.2019
Former [2019/45]AL31.10.2018
AT31.10.2018
CZ31.10.2018
DK31.10.2018
EE31.10.2018
ES31.10.2018
FI31.10.2018
HR31.10.2018
LT31.10.2018
LV31.10.2018
MC31.10.2018
NL31.10.2018
PL31.10.2018
RO31.10.2018
RS31.10.2018
SE31.10.2018
SK31.10.2018
SM31.10.2018
BG31.01.2019
NO31.01.2019
GR01.02.2019
IS28.02.2019
PT01.03.2019
Former [2019/40]AL31.10.2018
AT31.10.2018
CZ31.10.2018
DK31.10.2018
EE31.10.2018
ES31.10.2018
FI31.10.2018
HR31.10.2018
LT31.10.2018
LV31.10.2018
NL31.10.2018
PL31.10.2018
RO31.10.2018
RS31.10.2018
SE31.10.2018
SK31.10.2018
SM31.10.2018
BG31.01.2019
NO31.01.2019
GR01.02.2019
IS28.02.2019
PT01.03.2019
Former [2019/37]AL31.10.2018
AT31.10.2018
CZ31.10.2018
DK31.10.2018
EE31.10.2018
ES31.10.2018
FI31.10.2018
HR31.10.2018
LT31.10.2018
LV31.10.2018
NL31.10.2018
PL31.10.2018
RO31.10.2018
RS31.10.2018
SE31.10.2018
SM31.10.2018
BG31.01.2019
NO31.01.2019
GR01.02.2019
IS28.02.2019
PT01.03.2019
Former [2019/35]AL31.10.2018
AT31.10.2018
CZ31.10.2018
DK31.10.2018
ES31.10.2018
FI31.10.2018
HR31.10.2018
LT31.10.2018
LV31.10.2018
NL31.10.2018
PL31.10.2018
RS31.10.2018
SE31.10.2018
BG31.01.2019
NO31.01.2019
GR01.02.2019
IS28.02.2019
PT01.03.2019
Former [2019/34]AL31.10.2018
AT31.10.2018
DK31.10.2018
ES31.10.2018
FI31.10.2018
HR31.10.2018
LT31.10.2018
LV31.10.2018
NL31.10.2018
PL31.10.2018
RS31.10.2018
SE31.10.2018
BG31.01.2019
NO31.01.2019
GR01.02.2019
IS28.02.2019
PT01.03.2019
Former [2019/26]AL31.10.2018
AT31.10.2018
ES31.10.2018
FI31.10.2018
HR31.10.2018
LT31.10.2018
LV31.10.2018
NL31.10.2018
PL31.10.2018
RS31.10.2018
SE31.10.2018
BG31.01.2019
NO31.01.2019
GR01.02.2019
IS28.02.2019
PT01.03.2019
Former [2019/25]AT31.10.2018
ES31.10.2018
FI31.10.2018
HR31.10.2018
LT31.10.2018
LV31.10.2018
NL31.10.2018
PL31.10.2018
RS31.10.2018
SE31.10.2018
BG31.01.2019
NO31.01.2019
GR01.02.2019
IS28.02.2019
Former [2019/24]AT31.10.2018
ES31.10.2018
FI31.10.2018
HR31.10.2018
LT31.10.2018
LV31.10.2018
NL31.10.2018
PL31.10.2018
SE31.10.2018
BG31.01.2019
NO31.01.2019
GR01.02.2019
IS28.02.2019
Former [2019/23]AT31.10.2018
ES31.10.2018
FI31.10.2018
HR31.10.2018
LT31.10.2018
LV31.10.2018
NL31.10.2018
PL31.10.2018
BG31.01.2019
NO31.01.2019
IS28.02.2019
Former [2019/22]FI31.10.2018
LT31.10.2018
PL31.10.2018
BG31.01.2019
NO31.01.2019
IS28.02.2019
Former [2019/21]FI31.10.2018
LT31.10.2018
NO31.01.2019
IS28.02.2019
Former [2019/20]LT31.10.2018
NO31.01.2019
Cited inInternational search[X]   WEI Y-Q ET AL: "Immunogene therapy of tumors with vaccine based on Xenopus homologous vascular endothelial growth factor as a model antigen", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, NATIONAL ACADEMY OF SCIENCES, US, vol. 98, no. 20, 25 September 2001 (2001-09-25), pages 11545 - 11550, XP002248645, ISSN: 0027-8424, DOI: 10.1073/PNAS.191112198 [X] 13-17,24 * abstract *

DOI:   http://dx.doi.org/10.1073/pnas.191112198
ExaminationWO2007071947
 WO2005016126
by applicant  COTICCHIA ET AL., J. NATL. COMPR. CANE. NETW., vol. 6, no. 8, 2008, pages 795 - 802 [X] 13-17,24 * abstract *
   SAROJINI ET AL., JOURNAL OF ONCOLOGY, vol. 102, 2012 [I] 1-12,19-23
   CLAESSON-WELSH, L.: "VEGF-B Taken to Our Hearts: Specific Effect of VEGF-B in Myocardial Ischemia", ARTERIOSCLEROSIS, THROMBOSIS, AND VASCULAR BIOLOGY, vol. 28, no. 9, 2008, pages 1575 - 1576
   SHIN, Y. J.; J. S. CHOI ET AL.: "Induction of vascular endothelial growth factor receptor-3 mRNA in glial cells following focal cerebral ischemia in rats", J NEUROIMMUNOL, vol. 229, no. 1-2, 2010, pages 81 - 90
   GERSHONI, JM; ROITBURD-BERMAN, A; SIMAN-TOV, DD; TARNOVITSKI FREUND, N; WEISS, Y: "Epitope mapping: The first step in developing epitope-based vaccines", BIODRUGS, vol. 21, no. 3, 2007, pages 145 - 56, XP009103541, DOI: doi:10.2165/00063030-200721030-00002

DOI:   http://dx.doi.org/10.2165/00063030-200721030-00002
   WESTWOOD, MR; HAY, FC: "Epitope Mapping: a practical approach", 2001, OXFORD UNIVERSITY PRESS
   FLANAGAN ET AL.: "Mapping Epitopes with H/D-Ex Mass Spec", GENETIC ENGINEERING AND BIOTECHNOLOGY NEWS, vol. 31, no. 1, 2011
   GASEITSIWE, S.; VALENTINI, D.; MAHDAVIFAR, S.; REILLY, M.; EHMST, A.; MAEURER, M.: "Peptide Microarray-Based Identification of Mycobacterium tuberculosis Epitope Binding to HLA-DRB1 0101, DRB1*1501, and DRB1*0401", CLINICAL AND VACCINE IMMUNOLOGY, vol. 17, no. 1, 2009, pages 168 - 75, XP055137123, DOI: doi:10.1128/CVI.00208-09

DOI:   http://dx.doi.org/10.1128/CVI.00208-09
   LINNEBACHER, MICHAEL; LORENZ, PETER; KOY, CORNELIA; JAHNKE, ANNIKA; BORN, NADINE; STEINBECK, FELIX; WOLLBOLD, JOHANNES; LATZKOW, T: "Clonality characterization of natural epitope-specific antibodies against the tumor-related antigen topoisomerase IIa by peptide chip and proteome analysis: A pilot study with colorectal carcinoma patient samples", ANALYTICAL AND BIOANALYTICAL CHEMISTRY, vol. 403, no. 1, 2012, pages 227 - 38, XP035032766, DOI: doi:10.1007/s00216-012-5781-5

DOI:   http://dx.doi.org/10.1007/s00216-012-5781-5
   CRAGG, M. S.: "CD20 antibodies: Doing the time warp", BLOOD, vol. 118, no. 2, 2011, pages 219 - 20
   BANIK, SOMA S. R.; DORANZ, BENJAMIN J.: "Mapping Complex Antibody Epitopes", GENETIC ENGINEERING AND BIOTECHNOLOGY NEWS, vol. 3, no. 2, 2010, pages 25 - 8
   PAES, CHERYL; INGALLS, JADA; KAMPANI, KARAN; SULLI, CHIDANANDA; KAKKAR, ESHA; MURRAY, MEREDITH; KOTELNIKOV, VALERY; GREENE, TIFFAN: "Atomic-Level Mapping of Antibody Epitopes on a GPCR", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 131, no. 20, 2009, pages 6952 - 4
   "The Immunoassay Handbook", May 2005, ELSEVIER LTD
   HULTSCHIG C ET AL., CURR OPIN CHEM BIOL., vol. 10, no. 1, February 2006 (2006-02-01), pages 4 - 10
   "Kirk-Othmer, Encvclopedia of chemical techno", vol. 15, 1993, JOHN WILEY & SONS, pages: 518 - 562
   HANLEY ET AL., RADIOLOGY, vol. 143, 1982, pages 29 - 36
   DOWDY; WEARDEN: "Statistics for Research", 1983, JOHN WILEY & SONS
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.